Solventum Co. (NYSE:SOLV) Shares Acquired by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC boosted its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 7.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 75,283 shares of the company's stock after acquiring an additional 5,094 shares during the quarter. Wedge Capital Management L L P NC's holdings in Solventum were worth $4,973,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Copeland Capital Management LLC acquired a new position in shares of Solventum during the third quarter valued at approximately $26,000. Modus Advisors LLC purchased a new position in Solventum in the 4th quarter valued at $25,000. Mather Group LLC. acquired a new stake in Solventum during the 3rd quarter worth $27,000. Hollencrest Capital Management purchased a new stake in shares of Solventum during the second quarter worth $25,000. Finally, True Wealth Design LLC raised its position in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company's stock valued at $33,000 after buying an additional 471 shares during the last quarter.

Solventum Price Performance

SOLV traded up $0.91 during mid-day trading on Friday, hitting $73.60. 1,514,789 shares of the stock were exchanged, compared to its average volume of 741,976. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm's fifty day moving average is $69.12 and its two-hundred day moving average is $65.59. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05.

Analysts Set New Price Targets

A number of equities analysts recently commented on SOLV shares. Mizuho began coverage on Solventum in a research report on Wednesday, December 4th. They set a "neutral" rating and a $70.00 price objective on the stock. Piper Sandler boosted their price target on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a research report on Friday, November 8th. Stifel Nicolaus assumed coverage on shares of Solventum in a research note on Tuesday, October 8th. They set a "buy" rating and a $82.00 target price on the stock. Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a report on Monday, November 11th. Finally, Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They issued a "peer perform" rating on the stock. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Solventum currently has an average rating of "Hold" and an average price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.